SCHEMBL1056433

SCHEMBL1056433

CC1(C)Oc2ccc(Nc3nc(N[C@H]4CCCNC4)cc4nc[nH]c(=O)c34)nc2NC1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 17/20 0.60
JAK2 O60674 10/20 0.60
ZAP70 P43403 10/20 0.60
LYN P07948 9/20 0.60
RET P07949 2/20 0.41
FLT3 P36888 2/20 0.41
ALK Q9UM73 2/20 0.41
AURKB Q96GD4 4/20 0.41
KCNH2 Q12809 4/20 0.41
MAPK3 P27361 3/20 0.39
MAPK1 P28482 3/20 0.39
ADORA3 P0DMS8 2/20 0.39
TYRO3 Q06418 2/20 0.39
BMPR1B O00238 1/20 0.39
CDC7 O00311 1/20 0.39
PIK3CD O00329 1/20 0.39
PLK4 O00444 1/20 0.39
STK25 O00506 1/20 0.39
CIT O14578 1/20 0.39
RIOK3 O14730 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12932027 0.86 SYK (0.58) SYKJAK2ZAP70LYNRET
SCHEMBL3402852 0.81 SYK (0.56) SYKJAK2ZAP70LYNRET
SCHEMBL1053167 0.79 SYK (0.47) SYKJAK2ZAP70LYNRET
SCHEMBL1053859 0.79 SYK (0.71) SYKJAK2ZAP70LYNRET
SCHEMBL1053640 0.78 SYK (0.67) SYKJAK2ZAP70LYNRET
SCHEMBL13745953 0.78 SYK (0.67) SYKJAK2ZAP70LYNRET
SCHEMBL1051535 0.78 SYK (0.65) SYKJAK2ZAP70LYNRET
SCHEMBL3403293 0.76 SYK (0.64) SYKJAK2ZAP70LYNRET
SCHEMBL1053457 0.76 SYK (0.39) SYKJAK2ZAP70LYNRET
SCHEMBL1060374 0.75 SYK (0.63) SYKJAK2ZAP70LYNRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354526-B2 Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors IRM LLC (BM) 2013-01-15 US claimed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US claimed
US-8354526-B2 Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors IRM LLC (BM) 2013-01-15 US disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 US disclosed
WO-2009099801-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS ZAP70, FLT3, LCK SYK 18/4885JAK2 58/4885ZAP70 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.